Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters

Language
Document Type
Year range
3.
Journal of Heart & Lung Transplantation ; 41(4):S111-S112, 2022.
Article in English | Academic Search Complete | ID: covidwho-1783346

ABSTRACT

Although the currently approved COVID-19 vaccines are highly effective, SARS-CoV-2-specific immune responses are diminished in lung transplant recipients (LTR), probably due to immunosuppression (IS). There is currently no marker of IS that can be used to predict vaccination responses. Here, we study if torque tenovirus (TTV) can be used as a predictive marker. The humoral response to the mRNA-1273 vaccine was assessed in 103 LTR, who were vaccinated 4 to 237 months after Lung transplantation. Spike (S)-specific IgG levels were measured at baseline, 28 days after first, and 28 days after the second vaccination. TTV loads were determined by RT-PCR and Pearson's correlation coefficient was calculated to correlate serological responses to TTV load. Humoral responses to the vaccine COVID-19 vaccination were found in 41/103 (40%) LTR at 28 days after the second vaccination. 62 /103 (60%) had no detectable antibodies. TTV loads at baseline correlated with S-specific antibodies and the percentage of responders (=<0.001) (Fig 1). TTV loads also strongly correlated with the time since transplantation, indicating that participants with lower TTV loads were longer after transplantation. This study shows an association between baseline TTV load and mRNA-1273-induced S-specific antibodies. If the TTV load is indeed a predictor of vaccination responses, this can be used in the future as a potential guidance for optimizing vaccination regimens. Therefore, we recommend that TTV load measurements are included in further vaccination efficacy studies in immunocompromised cohorts. [ FROM AUTHOR] Copyright of Journal of Heart & Lung Transplantation is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

4.
Journal of Heart & Lung Transplantation ; 41(4):S54-S54, 2022.
Article in English | Academic Search Complete | ID: covidwho-1783340

ABSTRACT

In April 2020 COVID-19 lockdown measures were instigated leading to a dramatic drop in non-COVID respiratory virus infections (RVI). This provided a unique situation to assess the impact of RVI on annual FEV1 decline, episodes of temporary drop in lung function suggestive of infection (TDLF) and CLAD in lung transplant recipients (LTR). All lung function tests (LFT) of LTR transplanted between 2009-April 2020 were used from post-transplant baseline onward. LFT were censored after COVID-19 infection. Weekly RVI counts from the virology department defined RVI pressure over time. TDLF was defined as sudden, reversible FEV1 drop compared to previous 4 values (any TDLF ≥10% and ≥200ml, severe TDLF ≥20% and ≥500ml). Annual FEV1 decline was estimated using linear mixed effects models with separate estimates for 2009/20 and 2020/21. Effect modification by TDLF frequency of individual LTR (two subgroups, split at median) and RVI pressure was tested. Rates of CLAD and TDLF were analyzed over time. 479 LTR (12,775 LFT) were included. Annual FEV1 change in 2009/20 was -114ml [95%CI -133;-94], while in 2020/21 this was significantly less: 5ml [-38;48] (p<0.001). RVI pressure significantly affected FEV1 level (an increase in weekly RVI-count of 10 leading to a 7ml [-10;-5] lower FEV1 (p<0.001). FEV1 decline in 2009/20 was faster in frequent TDLF LTR vs. infrequent (-150ml [-181;-120] vs. -90ml [-115;-65] p=0.003 Fig A). 2020/21 showed significant decreases in number of any TDLF (OR 0.53 [0.33;0.85], p=0.008) and severe TDLF (OR 0.34 [0.16;0.71] p=0.005) and numerically lower CLAD (OR 0.53 [0.27;1.02] p=0.060). Effect modification by RVI pressure (Figures B-D) indicated an association between the events and RVI. During the lockdown year 2020/21 the broad decline in RVI coincided with substantially less FEV1 decline, TDLFs and possibly CLAD. All these outcomes were moderated by RVI pressure suggesting an important role for RVI in lung function decline in LTR. [ FROM AUTHOR] Copyright of Journal of Heart & Lung Transplantation is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

SELECTION OF CITATIONS
SEARCH DETAIL